Formoterol for Diabetic Kidney Disease
Formoterol in Diabetes
Recruiting
Phase 2
Interventional Study
Diabetic Nephropathies
Diabetic Kidney Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Medical University of South Carolina · Other
Who this trial is looking for
This trial is looking for adults with type 2 diabetes and diabetic kidney disease. Participants will either receive an additional treatment called formoterol or continue with their current treatments as usual.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 75 years old.
- I have been diagnosed with type 2 diabetes.
- I have been on stable medical therapy for at least 3 months.
- I have diabetic kidney disease confirmed by a nephrologist.
- I have a urine test showing 200-5000 mg of albumin per gram of creatinine.
- My HbA1c is less than 8%.
- I have been taking stable doses of medication for high blood pressure for at least 3 months.
- I can comply with the study requirements and give written consent.
You may not be able to join if
- I am pregnant or breastfeeding.
- I currently take beta-agonist medications.
- I have had serious heart problems in the last year.
- I have a history of asthma.
- My potassium levels are low.
- I have uncontrolled high blood pressure.
- I cannot take formoterol due to allergies.
- I have untreated cancer.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of n…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18-75
* Diagnosis of type 2 diabetes according to American Diabetes Association (ADA) criteria
* On stable medical therapy for at least 3 months
* Stage CKD G2 to G3b; A2-A3 as defined by eGFR with no requirement for renal biopsy for diagnosis
* Diabetic kidney dis…
Contacts